Maravai Lifesciences Holdings Inc Total Liabilities
Maravai Lifesciences Holdings Inc total liabilities. Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) has total liabilities worth $248.16 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MRVI cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Maravai Lifesciences Holdings Inc (2018–2025)
Total liabilities of Maravai Lifesciences Holdings Inc from 2018 to 2025. This chart illustrates how Maravai Lifesciences Holdings Inc's total liabilities have evolved over time, based on quarterly financial data.
Maravai Lifesciences Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Maravai Lifesciences Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norconsult ASA
OL:NORCO
|
Norway | Nkr4.47 Billion |
|
He Bei Cheng De LoLo Co Ltd
SHE:000848
|
China | CN¥1.20 Billion |
|
TTW Public Company Limited
BK:TTW-R
|
Thailand | ฿4.11 Billion |
|
Evolution Metals & Technologies Corp. Common Stock
NASDAQ:EMAT
|
USA | $113.94 Million |
|
Flow Traders BV
AS:FLOW
|
Netherlands | €15.08 Billion |
|
OMH SCIENCE Group Co Ltd
SHE:300486
|
China | CN¥1.38 Billion |
|
Hunan Valin Wire & Cable Co Ltd
SHE:001208
|
China | CN¥3.93 Billion |
|
Luoyang Longhua Heat Trans Energy
SHE:300263
|
China | CN¥3.92 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Maravai Lifesciences Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Maravai Lifesciences Holdings Inc.
Liquidity & Leverage Metrics
Maravai Lifesciences Holdings Inc Total Liabilities Ratios Explained
Maravai Lifesciences Holdings Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maravai Lifesciences Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maravai Lifesciences Holdings Inc (2018–2025)
The table below shows the annual total liabilities of Maravai Lifesciences Holdings Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $397.87 Million | -7.70% |
| 2024-12-31 | $431.04 Million | -38.21% |
| 2023-12-31 | $697.57 Million | -49.34% |
| 2022-12-31 | $1.38 Billion | +0.30% |
| 2021-12-31 | $1.37 Billion | +23.03% |
| 2020-12-31 | $1.12 Billion | +157.62% |
| 2019-12-31 | $433.17 Million | +10.60% |
| 2018-12-31 | $391.66 Million | -- |
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products fo… Read more